Boston Scientific announces schedule of presentations at EuroPCR 2016
WATCHMAN™ LAAC Device EWOLUTION Real-World Outcomes to be Featured as Late Breaking Clinical Trial

Boston Scientific (NYSE: BSX) today announced its schedule of key data, that will be featured at the annual EuroPCR Scientific Program, May 17-20 in Paris.

Data from the 1,000-patient EWOLUTION registry, the observational, prospective, non-randomized multicenter study of 'real-world' outcomes with the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device in Europe will be featured as a late-breaking clinical trial on Tuesday, May 17. The 1,000-patient RESPOND study, reporting the safety and efficacy of the Lotus™ Transcatheter Aortic Valve Replacement System used in routine clinical practice will be presented in a hot line session, also on Tuesday, May 17.

Other presentations and abstracts of interest include data supporting products in the Boston Scientific interventional cardiology portfolio. Oral presentations will include the final, five-year outcomes of the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System observed in the EVOLVE trial, as well as two-year clinical outcomes from the EVOLVE II Trial, which assesses the SYNERGY Stent in patients with diabetes. Additionally, there will be two oral abstracts which will examine the performance of the Lotus™ Valve.

“We are looking forward to facilitating engaging discussions of the data being presented at this year’s EuroPCR congress, including the late-breaking clinical data relating to the 'real-world' performance of the WATCHMAN Device, and increasing clinical data collection for patients treated with the SYNERGY Stent and Lotus Valve” said Keith Dawkins, M.D., global chief medical officer, Boston Scientific. “As reflected by our robust clinical strategy, we continue to pursue compelling evidence that supports advancing the standard of care.”


Tuesday, May 17

  • WATCHMAN LAAC Device: EWOLUTION: Three-month outcome of LAA closure in Europe: post-procedural drug regimen, impact of center experience and leakage. Data from the prospective 1,000 patient EWOLUTION Registry: Dr. M.W. Bergmann, MD, will present on Tuesday, May 17 at 12:08 in the Main Arena.
  • The Lotus Valve System: The RESPOND Study: safety and efficacy of a fully repositionable and retrievable aortic valve used in routine clinical practice: Professor Volkmar Falk, MD, will present on Tuesday, May 17 at 16:48 in Room Maillot.

Wednesday, May 18

  • WATCHMAN LAAC Device: Short-term (45 days) therapeutic anticoagulation following LAA closure has no effect on clinical outcomes: Dr. Maurice Buchbinder, MD, will present on Wednesday, May 18 at 9:22 in Room 343.
  • The Lotus Valve System: Safety and efficacy of a fully repositionable and retrievable transcatheter heart valve in patients with bicuspid aortic valve stenosis: an analysis from the RESPOND Study: Dr. Dan Blackman, MD, will present on Wednesday, May 18 at 11:35 in Room 343.

Thursday, May 19

  • SYNERGY Stent: Final five-year clinical outcomes in the EVOLVE Trial: a randomized evaluation of a novel bioabsorbable polymer-coated everolimus-eluting stent: Professor Ian Meredith, PhD, will present on Thursday, May 19 at 15:24 in Room 343.
  • PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System: PROMUS Element European Post-Approval (PE PROVE) 4-year outcomes: Four-year results from the multicenter PE-Prove Registry: outcomes in 1010 unselected patients treated with a platinum-chromium, everolimus-eluting stent: Dr. Raúl Moreno, MD, FESC, will present on Thursday, May 19 at 17:48 in Room 241.

Friday, May 20

  • Eluvia™ Drug-Eluting Vascular Stent System: Efficacy of a novel fluoropolymer-coated paclitaxel-eluting peripheral stent in a familial hypercholesterolemic swine model of balloon-injured femoral arteries: Professor T. Thomas Zeller, MD, will present on Friday, May 20, at 10:18 in the Arlequin Room.
  • SYNERGY Stent: Two-year clinical outcomes in the EVOLVE II Trial, Diabetes subset of a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: Professor Ian Meredith, PhD, will present on Friday, May 20 at 11:24 in Room 252A.


All events are Paris time and take place at the Palais des Congres. For more information, visit the Boston Scientific booth located on Level 1, Hall Passy F17.

In the U.S., the Lotus Valve and Eluvia Drug Eluting stent are investigational devices and are not available for sale.

DISCLAIMER: Please be informed that in some EU countries (Bulgaria, Cyprus, Estonia, France, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Slovakia, Belgium , Netherlands, Slovenia and Spain) medical device advertisement to general public is not permitted. Therefore, if you are accessing this website from one of those countries and you are not a healthcare professional, you need to exit this site immediately, since you would be viewing information that may not be legally allowed under the laws of your country of residence. Should you disregard this warning notice, Boston Scientific declines any liability as to your access to your access to such information.